Skip to content

    J B Chemicals &

    JBCHEPHARMGood
    Healthcare·31 Jul 2025
    Management Summary

    J B Chemicals delivered a strong start to FY26, characterized by record operating margins and continued outperformance in the domestic market. While international formulations faced temporary headwinds in Russia and the US, the CDMO segment and chronic domestic portfolio provided robust growth. Management maintained its full-year guidance despite the significant strategic announcement of a controlling stake acquisition by Torrent Pharma.

    Highlights

    8

    • Revenue reached ₹1,094 crore, representing a 9% year-on-year growth.

    • Adjusted Operating EBITDA grew 13% to ₹330 crore, excluding ESOP and one-off merger charges.

    • Operating EBITDA margin expanded 120 bps to 30.2%, the highest reported by the company to date.

    • Adjusted PAT (excluding one-offs) stood at ₹214 crore, a 21% increase over the previous year.

    • Domestic business outperformed the industry with 14% growth, reaching ₹678 crore.

    • Gross margins improved by 210 bps to 68.3% due to favorable mix and cost optimization.

    • CDMO business grew 8% to ₹115 crore, with a strong pipeline of 3-4 new launches expected in 12-18 months.

    • Torrent Pharma announced intention to acquire a 46.39% controlling stake from KKR at ₹1,639.18 per share.

    What Changed1

    vs Q3 FY26

    Guidance items6 → 5 (-1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹1,094 Cr+9%YoY
    2. 02Operating EBITDA (Adj)₹330 Cr+13%YoY
    3. 03EBITDA Margin (Adj)30.2%
    4. 04PAT (Adj)₹214 Cr+21%YoY
    5. 05Gross Margin68.3%

    Segment breakdown

    • Domestic Business₹678 Cr62.0%
    • International CDMO₹115 Cr10.5%
    • International Formulations₹283 Cr25.9%
    • API Vertical₹18 Cr1.6%
    Donut· Share of Revenue

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Domestic Revenue Growth Alpha
    12-14%
    		High
    Revenue
    CDMO Revenue Growth
    12-14%
    		High
    Margin
    Operating EBITDA Margin
    27-29%
    		High
    Margin
    Gross Margin (GC)
    67%
    		Medium
    Other
    Operating Cash Flow Conversion
    75-78%
    		High

    Risks & concerns

    5
    RiskSeverity

    US Generic Pricing Pressure

    Management noted slight pricing pressure for two key molecules in the US market, though they expect this to be neutralized in H2. — Management acknowledged

    medium

    International Market Volatility

    Russia saw a slow season and South Africa faced muted institutional growth, leading to a 2% decline in international formulations. — Both acknowledged

    medium

    Merger Integration and Regulatory Approvals

    Analysts questioned milestones for the Torrent acquisition; management referred only to the press release, citing 'business as usual' internally. — Analyst deflected

    medium

    Areas of Evasion(2)

    • Specific quarterly run rate for US sales
    • Detailed milestones for the Torrent acquisition/merger process

    Q&A highlights

    3

    “Our expenses, which is INR15 crore.”

    Clarifies the one-time impact of the Torrent merger scheme on the current quarter's profitability.

    asked by Rashmi, Dolat Capital

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Merger with Torrent Pharma

    On June 29, Torrent Pharma announced its intention to acquire KKR's 46.39% controlling stake in J B Chemicals for ₹11,917 crore, to be followed by a merger. The transaction triggers a mandatory tender offer at ₹1,639.18 per share. Management emphasized that despite the ownership change, operations remain 'business as usual' with a focus on existing strategic goals. The merger is subject to CCI and other regulatory approvals.

    02

    Domestic Market Outperformance

    The domestic business grew 14% YoY to ₹678 crore, significantly outperforming the industry's 9% growth. This growth was perfectly balanced with a 7% contribution from price and 7% from volume. The chronic portfolio led the way with 15% growth, while the ophthalmology segment grew 19%. Key brands like Sporlac and Razel crossed significant MAT milestones of ₹146 crore and ₹100 crore, respectively.

    03

    CDMO Pipeline and Run-Rate

    The CDMO segment grew 8% in Q1 to ₹115 crore, with management guiding for 12-14% growth for the full year. The company has already dispatched first commercial quantities of new products like Iodine Liquid and Throat Spray to Asia Pac and EU markets. Management expects 3 to 4 important new launches in the next 12 to 18 months, with the quarterly run rate expected to rise from ₹120 crore in H1 to ₹130 crore in H2.

    04

    International Formulation Headwinds

    International formulations revenue declined 2% YoY to ₹283 crore due to a slow season in Russia and muted institutional growth in South Africa. The US market also faced pricing pressure on two key molecules. However, management remains optimistic about a recovery in the second half of the year, citing good order visibility and a pipeline of 8-10 molecules across 14-16 key ROW markets starting in Q4.

    05

    Record Margin Profile and Cost Efficiency

    J B Chemicals achieved a record operating EBITDA margin of 30.2%, up 120 bps YoY, driven by a 210 bps expansion in gross margins to 68.3%. This was aided by a favorable business mix and consistent cost optimization initiatives. Despite a 16% increase in staff costs due to increments and incentives, the company maintains its full-year EBITDA margin guidance of 27-29%, aiming for the upper end of that range.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.